GlassScriptPhysician profile
Ginger R Brooks
NPI 1881998078
$3,256.58
in general payments reported to CMS, 2019-2025
30 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $339 · 2024: $682 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.30 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $536.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,271.92 | 2024-2025 | |
| Lilly USA, LLC | $379.07 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Abbvie INC. | $226.72 | 2023-2025 | |
| Tempus Ai, INC | $175.68 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $106.53 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Incyte Corporation | $99.95 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $95.83 | 2025 | Opdivo |
| Merck Sharp & Dohme LLC | $85.06 | 2024-2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $73.12 | 2025 | |
| Karyopharm Therapeutics INC. | $59.01 | 2024-2025 | Xpovio |
| Genzyme Corporation | $54.64 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $50.89 | 2023-2025 | Myrisk, Precisetumor |
| Caris Mpi, INC. | $50.69 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $48.53 | 2024-2025 | |
| Genentech USA, INC. | $47.73 | 2025 | Tecentriq, Venclexta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.81 | 2024-2025 | Vyloy, Xtandi |
| Gilead Sciences, INC. | $41.99 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $41.84 | 2024-2025 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $37.98 | 2025 | |
| Celgene Corporation | $37.74 | 2024 | Reblozyl |
| Pharmaessentia USA Corporation | $32.71 | 2025 | Besremi |
| Array Biopharma INC | $31.49 | 2025 | Xalkori, Braftovi, Mektovi |
| Eisai INC. | $29.24 | 2024 | |
| Aveo Pharmaceuticals, INC. | $25.58 | 2024 | |
| Taiho Oncology, INC. | $24.96 | 2025 | |
| Sobi, INC | $21.19 | 2025 | |
| Rigel Pharmaceuticals, INC. | $16.75 | 2024 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $16.49 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2024 | Fruzaqla |
| Syndax Pharmaceuticals, INC. | $14.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.